Log In
BCIQ
Print this Print this
 

CXL, CXL104 (formerly CEF104)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionCombination of avibactam, a beta lactamase (LACTB) inhibitor, and Zinforo ceftaroline fosamil, a c ephalosporin antibiotic
Molecular Target Beta lactamase (LACTB)
Mechanism of ActionBeta lactamase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationStaphylococcus
Indication DetailsTreat methicillin-resistant Staphylococcus aureus (MRSA) infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,575.0M

$725.0M

$850.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/24/2016

$1,575.0M

$725.0M

$850.0M

Get a free BioCentury trial today